Aquestive Therapeutics Inc (AQST) concluded trading on Wednesday at a closing price of $4.38, with 3.63 million shares of worth about $15.9 million changed hands on the day. Half year performance of the stock remained positive as price took a surge of 212.86% during that period and on April 3, 2024 the price saw a gain of about 5.80%. Currently the company’s common shares owned by public are about 89.97M shares, out of which, 83.74M shares are available for trading.
However, the stock later moved at a day high price of 5.6100, or with a gain of 5.80%. Stock saw a price change of 7.88% in past 5 days and over the past one month there was a price change of 4.78%. Year-to-date (YTD), AQST shares are showing a performance of 116.83% which increased to 284.21% when we look at its performance for past 12 months. Over the period of past 52 weeks, stock dropped to lowest price of $1.01 but also hit the highest price of $6.23 during that period. The average intraday trading volume for Aquestive Therapeutics Inc shares is 2.14 million. The stock is currently trading -8.35% below its 20-day simple moving average (SMA20), while that difference is up 22.01% for SMA50 and it goes to 94.13% higher than SMA200.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
Aquestive Therapeutics Inc (NASDAQ: AQST) currently have 89.97M outstanding shares and institutions hold larger chunk of about 26.45% of that.
The stock has a current market capitalization of $394.07M and its 3Y-monthly beta is at 2.91. It has posted earnings per share of -$0.14 in the same period. It has Quick Ratio of 1.87. Volatility of a stock is a metric used to know how much the price of that stock is under influence and for AQST, volatility over the week remained 7.23% while standing at 11.90% over the month.
Stock’s fiscal year EPS is expected to drop by -187.91% while it is estimated to increase by 18.51% in next year.
Digging deeper we find that several firms have released their research notes about the support levels of the stock. Most recent of them is a note released by Raymond James on March 28, 2024 offering an Outperform rating for the stock and assigned a target price of $7 to it. Coverage by RBC Capital Mkts stated Aquestive Therapeutics Inc (AQST) stock as an Outperform in their note to investors on April 07, 2021, suggesting a price target of $7 for the stock. On April 22, 2019, H.C. Wainwright Initiated their recommendations, while on January 03, 2019, Lake Street Initiated their ratings for the stock with a price target of $14. Stock get an Outperform rating from RBC Capital Mkts on August 20, 2018.
